Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486881 | 0.75 | — | — | |
| SCHEMBL3071835 | 0.75 | MMP1 (0.38) | MMP1CA2MMP8MMP2CA12 | |
| SCHEMBL18279841 | 0.75 | ALDH1A1 (0.48) | ALDH1A1BCHEHIF1AMMP1CA2 | |
| SCHEMBL21418523 | 0.74 | MMP1 (0.34) | MMP1CA2MMP8MMP2CA12 | |
| Hydrochloric Acid SCHEMBL11815969 | 0.73 | ALDH1A1 (0.46) | ALDH1A1BCHEHIF1AMMP1CA2 | |
| Hydrochloric Acid SCHEMBL28132101 | 0.73 | — | — | |
| SCHEMBL5962279 | 0.73 | — | — | |
| SCHEMBL762525 | 0.73 | — | — | |
| SCHEMBL11794902 | 0.71 | ALDH1A1 (0.34) | ALDH1A1BCHEHIF1AMMP1CA2 | |
| SCHEMBL10120978 | 0.71 | CA14 (0.43) | ALDH1A1BCHEHIF1AMMP1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102439025-B | RNA synthesizes-is used for inverse composition RNA phosphoramidite, and synthesizes in 3 ' ends the application in RNA the facilitating the introduction of of part, chromophore and trim | 坎姆根公司 | 2017-08-01 | — | — | CN | disclosed |
| US-20160346440-A1 | TROPOELASTIN FOR PROMOTING ENDOTHELIAL CELL ADHESION OR MIGRATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2016-12-01 | — | — | US | disclosed |
| US-9381282-B2 | Tropoelastin for promoting endothelial cell adhesion or migration | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150182589-A1 | TREATMENT OF MUSCULAR DYSTROPHIES AND RELATED DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
| US-20150151028-A1 | Tropoelastin for Promoting Endothelial Cell Adhesion or Migration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-9005356-B2 | Tropoelastin for promoting endothelial cell adhesion or migration | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-14 | — | — | US | disclosed |
| US-8822418-B2 | Treatment of muscular dystrophies and related disorders | BROWN UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8729013-B2 | Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2014-05-20 | — | — | US | disclosed |
| US-20120322849-A1 | Methods of Inhibiting Staphylobactin-mediated Iron Uptake in S. aureus | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2012-12-20 | — | — | US | disclosed |
| US-20120259091-A1 | Apolipoprotein A1 Mimetics and Uses Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2012-10-11 | — | — | US | disclosed |
| US-7612038-B2 | Stabilizing dystrophin associated protein complexes; abnormal synapses or neuromuscular junction disorders | BROWN UNIVERSITY (US) | 2009-11-03 | — | — | US | disclosed |
| US-7524811-B2 | Anti-angiogenic peptides from the N-terminus of endostatin | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080241099-A1 | Inhibitors of MBP 85-99 or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones; multiple sclerosis; rheumatoid arthritis; solid phase synthesis; kits | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-02 | — | — | US | disclosed |
| US-20080241099-A1 | Inhibitors of MBP 85-99 or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones; multiple sclerosis; rheumatoid arthritis; solid phase synthesis; kits | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-02 | — | — | US | disclosed |
| US-20080194462-A1 | Methods and Compositions for Treatment of Autoimmune Diseases | PEPTIMMUNE, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7381790-B2 | For therapy of multiple sclerosis (MS) in humans | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-06-03 | — | — | US | disclosed |
| US-20080050361-A1 | STAPHYLOCOCCUS AUREAS SPECIFIC ANTI-INFECTIVES | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2008-02-28 | — | — | US | disclosed |
| US-20070292873-A1 | Bacterial iron acquisition targets | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2007-12-20 | — | — | US | disclosed |
| US-7235244-B2 | Compositions and methods for treating papillomavirus-infected cells | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070129440-A1 | Polypharmacophoric agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322849-A1 | Methods of Inhibiting Staphylobactin-mediated Iron Uptake in S. aureus | SLC40A1, HAMP, SLC7A1 | ALDH1A1 4244/4885BCHE 3437/4885HIF1A 1030/4885 |
| US-20080241099-A1 | Inhibitors of MBP 85-99 or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones; multiple sclerosis; rheumatoid arthritis; solid phase synthesis; kits | HLA-DRB1, CD74, HYPK | ALDH1A1 4858/4885BCHE 2736/4885HIF1A 3942/4885 |
| US-20150182589-A1 | TREATMENT OF MUSCULAR DYSTROPHIES AND RELATED DISORDERS | MUSK, CHRNA6, MYLK2 | ALDH1A1 4730/4885BCHE 1373/4885HIF1A 4485/4885 |
| US-20080050361-A1 | STAPHYLOCOCCUS AUREAS SPECIFIC ANTI-INFECTIVES | CUTA, HIRA, SP1 | ALDH1A1 1162/4885BCHE 1096/4885HIF1A 262/4885 |
| US-20120259091-A1 | Apolipoprotein A1 Mimetics and Uses Thereof | APOB, APOL1, CETP | ALDH1A1 2215/4885BCHE 1535/4885HIF1A 1257/4885 |
| US-20080194462-A1 | Methods and Compositions for Treatment of Autoimmune Diseases | HLA-DRB1, CD74, HLA-B | ALDH1A1 4808/4885BCHE 1145/4885HIF1A 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.